NCT03990051View on ClinicalTrials.gov

Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT.

PHASE2CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

October 17, 2019

Primary Completion Date

October 31, 2021

Study Completion Date

November 19, 2021

Conditions
Chronic Ocular Graft-versus-host Disease
Interventions
DRUG

Pro-ocular™ topical gel

Topical gel for forehead dermal application

DRUG

Placebo topical gel

Topical gel for forehead dermal application

Trial Locations (1)

02115

Massachusetts Eye and Ear Longwood, Boston

All Listed Sponsors
collaborator

ORA, Inc.

INDUSTRY

lead

Glia, LLC

INDUSTRY

NCT03990051 - Treatment Safety and Efficacy of Pro-ocular™ 1% for Chronic Ocular Graft Following Allogeneic HSCT. | Biotech Hunter | Biotech Hunter